How are women with SUI-symptoms treated with duloxetine in real life practice? - preliminary results from a large observational study in Germany

International Journal of Clinical Practice
Martina ManningMartin C Michel

Abstract

Duloxetine was found safe and effective in the treatment of moderate to severe female stress urinary incontinence (SUI) in controlled clinical trials; complementary data from routine clinical practice are still wanted. To explore the use of various initial duloxetine doses by physicians in the treatment of female SUI in routine clinical practice and its implications on drug safety and patients' subjective impression of effectiveness. Adult women treated with duloxetine for SUI symptoms were documented as part of an ongoing large-scale observational study in Germany. Data collected at baseline, after 4 and 12 weeks, were evaluated by initial doses. Statistics were descriptive, 95% confidence intervals were calculated for adverse event (AE) rates. A total of 7888 adult women were treated with duloxetine; their mean age was 61.4 years, body mass index 27 kg/m(2), incontinence episode frequency (IEF) 14.0 per week. Previous SUI treatments were observed in 52.2%, comorbidities in 60.4% of the patients. A total of 90.7% reported reduced frequency of SUI-episodes, 12.1% any AE; nausea (5.7%) and vertigo (1.6%) were reported most frequently. In all, 52.2% of patients were initiated on a duloxetine dose of 40 mg/day. Only minor differen...Continue Reading

References

Dec 7, 2000·Journal of Clinical Epidemiology·Y S HannestadUNKNOWN Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag
Jul 13, 2002·American Journal of Obstetrics and Gynecology·Peggy A NortonUNKNOWN Duloxetine Urinary Incontinence Study Group
Jul 26, 2002·Brain Research·Karl B ThorJohn M Schaus
Feb 1, 2003·Urology·Paul AbramsUNKNOWN Standardisation Sub-Committee of the International Continence Society
Sep 23, 2003·The Journal of Urology·Roger R DmochowskiUNKNOWN Duloxetine Urinary Incontinence Study Group
Oct 11, 2003·Urology·Steinar HunskaarMarie Carmela Lapitan
Feb 7, 2004·BJU International·R J MillardUNKNOWN Duloxetine UI Study Group
Feb 14, 2004·BJOG : an International Journal of Obstetrics and Gynaecology·Philip van KerrebroeckUNKNOWN Duloxetine Urinary Incontinence Study Group
Aug 11, 2004·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·K B Thor
Aug 11, 2004·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Kate Moore
Sep 2, 2004·Obstetrics and Gynecology·Linda CardozoRichard C Bump
Dec 22, 2004·BJU International·Vera VandoninckUNKNOWN UREPIK study group
Sep 29, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Daniel J HurleySimin K Baygani
Dec 13, 2006·International Urogynecology Journal and Pelvic Floor Dysfunction·David Castro-DiazUNKNOWN Duloxetine Dose Escalation Study Group

❮ Previous
Next ❯

Citations

Mar 8, 2014·International Urogynecology Journal·Nadine Schwertner-TiepelmannRalf Tunn

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

BJOG : an International Journal of Obstetrics and Gynaecology
M OelkeMartin C Michel
European Journal of Obstetrics, Gynecology, and Reproductive Biology
Daniel J HurleySimin K Baygani
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Borislava MihaylovaMark Sculpher
© 2022 Meta ULC. All rights reserved